Jann-Yuan Wang1, Ming-Chia Lee2, Chin-Chung Shu3, Chih-Hsin Lee4, Li-Na Lee5, Kun-Mao Chao6, Feng-Yee Chang7. 1. Department of Internal Medicine, National Taiwan University Hospital, Taipei. 2. Department of Pharmacy Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation, New Taipei. 3. Department of Traumatology, National Taiwan University Hospital, Taipei. 4. Department of Pulmonary Medicine Wanfang Hospital, Taipei Medical University, Taipei. Electronic address: chlee.tw@gmail.com. 5. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei. 6. Graduate Institute of Biomedical Electronics and Bioinformatics National Taiwan University, Taipei. 7. Centers for Disease Control Taipei, Taiwan.
Abstract
BACKGROUND: Diabetes mellitus (DM) increases the risk of TB recurrence. This study investigated whether 9-month anti-TB treatment is associated with a lower risk of TB recurrence within 2 years after complete treatment than 6-month treatment in patients with DM with an emphasis on the impact of directly observed therapy, short course (DOTs). METHODS: Patients with pulmonary but not extrapulmonary TB receiving treatment of 173 to 277 days between 2002 and 2010 were identified from the National Health Insurance Research Database of Taiwan. Patients with DM were then selected and classified into two groups based on anti-TB treatment duration (9 months vs 6 months). Factors predicting 2-year TB recurrence were explored using Cox regression analysis. RESULTS: Among 12,688 patients with DM and 43,195 patients without DM, the 2-year TB recurrence rate was 2.20% and 1.38%, respectively (P < .001). Of the patients with DM, recurrence rate decreased from 3.54% to 1.19% after implementation of DOTs (P < .001). A total of 4,506 (35.5%) were classified into 9-month anti-TB treatment group. Although a 9-month anti-TB treatment was associated with a lower recurrence rate (hazard ratio, 0.76 [95% CI, 0.59-0.97]), the benefit disappeared (hazard ratio, 0.69 [95% CI, 0.43-1.11]) under DOTs. Other predictors of recurrence included older age, male sex, malignancy, earlier TB diagnosis year, culture positivity after 2 months of anti-TB treatment, and anti-TB treatment being ≤ 80% consistent with standard regimen. CONCLUSIONS: The 2-year TB recurrence rate is higher in a diabetic population in Taiwan and can be reduced by treatment supervision. Extending the anti-TB treatment by 3 months may also decrease the recurrence rate when treatment is not supervised.
BACKGROUND:Diabetes mellitus (DM) increases the risk of TB recurrence. This study investigated whether 9-month anti-TB treatment is associated with a lower risk of TB recurrence within 2 years after complete treatment than 6-month treatment in patients with DM with an emphasis on the impact of directly observed therapy, short course (DOTs). METHODS:Patients with pulmonary but not extrapulmonary TB receiving treatment of 173 to 277 days between 2002 and 2010 were identified from the National Health Insurance Research Database of Taiwan. Patients with DM were then selected and classified into two groups based on anti-TB treatment duration (9 months vs 6 months). Factors predicting 2-year TB recurrence were explored using Cox regression analysis. RESULTS: Among 12,688 patients with DM and 43,195 patients without DM, the 2-year TB recurrence rate was 2.20% and 1.38%, respectively (P < .001). Of the patients with DM, recurrence rate decreased from 3.54% to 1.19% after implementation of DOTs (P < .001). A total of 4,506 (35.5%) were classified into 9-month anti-TB treatment group. Although a 9-month anti-TB treatment was associated with a lower recurrence rate (hazard ratio, 0.76 [95% CI, 0.59-0.97]), the benefit disappeared (hazard ratio, 0.69 [95% CI, 0.43-1.11]) under DOTs. Other predictors of recurrence included older age, male sex, malignancy, earlier TB diagnosis year, culture positivity after 2 months of anti-TB treatment, and anti-TB treatment being ≤ 80% consistent with standard regimen. CONCLUSIONS: The 2-year TB recurrence rate is higher in a diabetic population in Taiwan and can be reduced by treatment supervision. Extending the anti-TB treatment by 3 months may also decrease the recurrence rate when treatment is not supervised.
Authors: Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton Journal: Tuberculosis (Edinb) Date: 2018-10-01 Impact factor: 3.131
Authors: Julia A Critchley; Blanca I Restrepo; Katharina Ronacher; Anil Kapur; Andrew A Bremer; Larry S Schlesinger; Randall Basaraba; Hardy Kornfeld; Reinout van Crevel Journal: Chest Date: 2017-04-20 Impact factor: 9.410
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079
Authors: A D Harries; A M V Kumar; S Satyanarayana; Y Lin; R Zachariah; K Lönnroth; A Kapur Journal: Int J Tuberc Lung Dis Date: 2015-08 Impact factor: 2.373
Authors: Jilson L Almeida-Junior; Leonardo Gil-Santana; Carolina A M Oliveira; Simone Castro; Aparecida S Cafezeiro; Carla Daltro; Eduardo M Netto; Hardy Kornfeld; Bruno B Andrade Journal: PLoS One Date: 2016-04-14 Impact factor: 3.240
Authors: Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Yan Lin; Rony Zachariah; Knut Lönnroth; Anil Kapur Journal: Trans R Soc Trop Med Hyg Date: 2016-03 Impact factor: 2.184